Table 3.
Cox regression analysis of overall survival in the entire patient cohorta
| Entire cohort (n = 281) | ||||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate* | |||||
| Prognostic factor | HR | (95% CI) | P value | HR | (95% CI) | P value |
| Cytoplasmic Msx2 (high vs. low, ref) | 0.69 | 0.49-0.97 | 0.031 | 0.58 | 0.36-0.93 | 0.023 |
| Age (continuous) | 1.06 | 1.05-1.07 | <0.001 | 1.05 | 1.03-1.07 | <0.001 |
| Tumour size (continuous) | 1.01 | 1.00-1.01 | <0.001 | 1.01 | 1.00-1.02 | 0.006 |
| Tumour grade (3 vs. 0-2, ref) | 2.09 | 1.63-2.67 | <0.001 | 1.78 | 1.06-2.99 | 0.028 |
| Nodal status (pos vs. neg, ref) | 3.18 | 2.43-4.16 | <0.001 | 3.06 | 1.95-4.80 | <0.001 |
| ER (pos vs. neg, ref) | 0.73 | 0.52-1.02 | 0.062 | 0.92 | 0.38-2.21 | 0.855 |
| PR (pos vs. neg, ref) | 0.61 | 0.46-0.81 | 0.001 | 0.68 | 0.41-1.13 | 0.140 |
| Her2 (3 vs. 0-2, ref) | 0.77 | 0.49-1.22 | 0.270 | 0.63 | 0.23-1.69 | 0.355 |
| Ki-67 (>10% vs. <10%, ref) | 1.31 | 1.01-1.71 | 0.044 | 1.15 | 0.67-1.97 | 0.610 |
aMsx2, muscle segment homeobox 2; ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor 2; Ki67, proliferation-related Ki-67 antigen. *Adjusted for all other variables in the table; ref, referent group.